Johnson & Johnson (J&J) has agreed to pay $132 per share to acquire Intra-Cellular Therapies Inc. in a deal valued at about $14.6 billion, taking ownership of Caplyta (lumateperone), a once-daily oral ...
NDA submitted to U.S. FDA for CAPLYTA® as adjunctive treatment for major depressive disorder; if approved, CAPLYTA® has ...
Johnson & Johnson acquires Intra-Cellular Therapies for $14.6 billion. The biggest driver was the rights Caplyta which has ...
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...
Shares of Lululemon Athletica Inc. ( LULU-Q +0.65% ) were higher by 0.9 per cent on Monday after it raised its ...
Andy Extance charts how research into revolutionary targeted protein degradation therapies is moving from serendipity to ...
VANCOUVER, BC / ACCESSWIRE / January 8, 2025 / StimCell Energetics Inc. (OTC PINK:STME) ("StimCell", or the "Company") a biotech company targeting cellular energy to promote anti-aging, longevity and ...
FY2024 revenue up 7% YoY, driven by international demand. Find out why I am upgrading CTKB stock from Hold to Buy.
Safehome.org on MSN3d
Home Security Systems: Your Options for 2025Getting to Know Home Security Systems Your home should always be where you feel the most safe and secure. But, the sanctity ...
Amazon this week is providing record low prices on multiple models of the iPad mini 7, starting at $399.00 for the 128GB ...
Simon was powered by an NEC V30HL processor with a clock speed of 16MHz. It included 1MB RAM and 1MB flash memory, expandable ...
The U.S. suffers from a disproportionately large share of global credit card fraud. Bringing customer authentication methods ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback